Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was 100% effective against severe versions of Covid-19.

NVAX Stock Is Not For The Faint Of Heart

In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.

Novavax (NVAX) Gains But Lags Market: What You Should Know

It involves producing a vaccine in great volume.

This is Novavax's Biggest Challenge Right Now

Cummins

Value stocks have a knack for outperforming during the early stages of an economic recovery.

3 Value Stocks That'll Make You Richer in July (and Beyond)

BioNTech SE

Johnson & Johnson

Moderna

Pfizer

Is the U.S. Buying Too Many COVID Vaccine Doses?

Let's use recent efficacy data as a starting point.

Can Novavax Beat Moderna and Pfizer in Preventing Severe COVID?

Novavax has made material progress since the disappointing lows of early May 2021.

Novavax Needs A 1:6 Share Split, For An Inviting Opportunity

Wall Street expects gains in the coming year.

How High Can Novavax's Shares Go?

Shares of Novavax Inc. were up 2.5% in premarket trading on Thursday, the day after The New England Journal of Medicine published a "final analysis" looking at how Novavax's COVID-19 vaccine candidate performed in a Phase 3 clinical trial conducted in 15,000 participants in the U.K. An earlier analysis of the data was previously published as a preprint. According to the new study, Novavax's experimental vaccine has an overall efficacy rate of 96.4% against the original strain of the virus and an 86.3% efficacy rate against the Alpha variant, which was first identified in the U.K. and has been the most dominant form of the virus in many countries since the start of the year.

Novavax's experimental COVID-19 shot has 86.4% efficacy against the Alpha variant

Here's What May Drive Novavax Shares Higher

This Is Novavax's Biggest Opportunity Right Now

The long-term answer could be different than the short-term answer.

How Big of a Splash Might Novavax Make in the COVID Vaccine Market?

GAITHERSBURG, Md., June 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM).

Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine

Editas Medicine

Intellia Therapeutics

Biotech stocks can be risky. If a clinical trial fails, you could very well lose your money.

The 3 Biotech Firms Riding High on CRISPR News

For now, at least, the answer appears to be "yes."

Is Novavax the Leader in Developing a Combo COVID/Flu Vaccine?

The results were great news, but widely expected.

Here's Why Novavax's Solid Vaccine Data Didn't Move the Stock

All three vaccines have similar efficacy and safety profiles, but Novavax's vaccine might have a few advantages.

Is Novavax's COVID-19 Vaccine Superior to the mRNA Vaccines?

Positive phase 3 data and good news from the Biden administration have sent Novavax shares flying in June.

Why Has Novavax Stock Been Jumping Higher?

The biotech stocks jumped for different reasons.

Why COVID Vaccine Stocks Moderna, Novavax, and BioNTech Soared This Week

In the latest trading session, Novavax (NVAX) closed at $192.24, marking a -1.1% move from the previous day.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

The Novavax vaccine does not require cold storage and could soon be available in international markets. The post Novavax Is a Long-Term Buy for the Continuing Pandemic appeared first on InvestorPlace.

Novavax Is a Long-Term Buy for the Continuing Pandemic

This coronavirus vaccine developer is near the finish line to the already-decided vaccine race.

Is Now the Time to Go All-In On Novavax Stock?

Salesforce

Green Thumb Industries Inc.

Pinterest

These blazing-hot deals won't last for long.

Got $10,000? Here Are Summer's Hottest Stocks to Buy

Let's look at data -- and other points needed for market dominance.

How Does Novavax Stack Up Against Today's Vaccine Leaders?

Good news for one COVID-19 vaccine maker ended up being bad news for all.

News for Novavax Stock (NVAX)